Cargando…

Prognostic Implication of KRAS G12C Mutation in a Real-World KRAS-Mutated Stage IV NSCLC Cohort Treated With Immunotherapy in The Netherlands

INTRODUCTION: With the approval of G12C inhibitors as the second line of treatment for KRAS G12C-mutated NSCLC, and the expanding research regarding targeting KRAS, it is key to understand the prognostic implication of KRAS G12C in the current first line of treatment. We compared overall survival (O...

Descripción completa

Detalles Bibliográficos
Autores principales:	Noordhof, Anneloes L., Swart, Esther M., Damhuis, Ronald A.M., Hendriks, Lizza E.L., Kunst, Peter W.A., Aarts, Mieke J., van Geffen, Wouter H.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2023
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10477684/ https://www.ncbi.nlm.nih.gov/pubmed/37674812 http://dx.doi.org/10.1016/j.jtocrr.2023.100543

Ejemplares similares

Overall survival in advanced epidermal growth factor receptor mutated non-small cell lung cancer using different tyrosine kinase inhibitors in The Netherlands: a retrospective, nationwide registry study
por: Gijtenbeek, Rolof G.P., et al.
Publicado: (2023)

Implications of KRAS mutations in acquired resistance to treatment in NSCLC
por: Del Re, Marzia, et al.
Publicado: (2017)

A Radiogenomics Ensemble to Predict EGFR and KRAS Mutations in NSCLC
por: Moreno, Silvia, et al.
Publicado: (2021)

Kras mutations increase telomerase activity and targeting telomerase is a promising therapeutic strategy for Kras-mutant NSCLC
por: Liu, Weiran, et al.
Publicado: (2016)

KRAS G12C Mutations in NSCLC: From Target to Resistance
por: Addeo, Alfredo, et al.
Publicado: (2021)

Adagrasib: A landmark in the KRAS(G12C)‐mutated NSCLC
por: Tian, He, et al.
Publicado: (2022)

Canadian Consensus Recommendations on the Management of KRAS G12C-Mutated NSCLC
por: Cheema, Parneet K., et al.
Publicado: (2023)

A Long Overdue Targeted Treatment for KRAS Mutations in NSCLC: Spotlight on Adagrasib
por: Brazel, Danielle, et al.
Publicado: (2022)

Dysregulation of KRAS signaling in pancreatic cancer is not associated with KRAS mutations and outcome
por: Lemstrova, Radmila, et al.
Publicado: (2017)

KRAS mutations and endometriosis burden of disease
por: Orr, Natasha L, et al.
Publicado: (2023)

Wee1 inhibitor MK1775 sensitizes KRAS mutated NSCLC cells to sorafenib
por: Caiola, Elisa, et al.
Publicado: (2018)

Phase 1 Clinical Trial of Trametinib and Ponatinib in Patients With NSCLC Harboring KRAS Mutations
por: Arbour, Kathryn C., et al.
Publicado: (2021)

Response to immunotherapy in KRAS G12C mutated NSCLC: a single-centre retrospective observational study
por: Sciortino, Carolina, et al.
Publicado: (2022)

The Therapeutic Landscape for KRAS-Mutated Colorectal Cancers
por: Tria, Simon Manuel, et al.
Publicado: (2023)

The current landscape of using direct inhibitors to target KRAS(G12C)-mutated NSCLC
por: Batrash, Firas, et al.
Publicado: (2023)

Establishment and Optimization of Radiomics Algorithms for Prediction of KRAS Gene Mutation by Integration of NSCLC Gene Mutation Mutual Exclusion Information
por: Wang, Jingyi, et al.
Publicado: (2022)

KRAS in NSCLC: State of the Art and Future Perspectives
por: Cascetta, Priscilla, et al.
Publicado: (2022)

Clinical Characteristics and Outcomes in Advanced KRAS-Mutated NSCLC: A Multicenter Collaboration in Asia (ATORG-005)
por: Lee, Jiyun, et al.
Publicado: (2021)

Impact of KRAS Mutation Subtypes and Co-Occurring Mutations on Response and Outcome in Advanced NSCLC Patients following First-Line Treatment
por: Sun, Yingjia, et al.
Publicado: (2022)

EGFR and KRAS Mutations in Lung Parenchyma of Subjects With EGFR/KRAS Wild-Type Lung Adenocarcinoma
por: Chalela, Roberto, et al.
Publicado: (2021)

KRAS and EGFR mutations coexisting in lung adenocarcinoma
por: Sousa, Vitor, et al.
Publicado: (2010)

KRAS and TP53 Mutations in Colorectal Carcinoma
por: Al-Kuraya, Khawla S.
Publicado: (2009)

Impact of KRAS Mutations on Management of Colorectal Carcinoma
por: Sullivan, Kevin M., et al.
Publicado: (2011)

EGFR and KRAS Mutations in Patients With Adenocarcinoma of the Lung
por: Jang, Tae Won, et al.
Publicado: (2009)

Heterogeneity of KRAS Mutation Status in Rectal Cancer
por: Jo, Peter, et al.
Publicado: (2016)

KRAS mutation: from undruggable to druggable in cancer
por: Huang, Lamei, et al.
Publicado: (2021)

KRAS mutations in patients with colorectal cancer in Libya
por: Abudabous, Asma, et al.
Publicado: (2021)

KRAS Mutations in Squamous Cell Carcinomas of the Lung
por: Acker, Fabian, et al.
Publicado: (2021)

Characterization of KRAS Mutational Regression in Oligometastatic Patients
por: Ottaiano, Alessandro, et al.
Publicado: (2022)

Prognostic and Predictive Roles of KRAS Mutation in Colorectal Cancer
por: Arrington, Amanda K., et al.
Publicado: (2012)

Kras(P34R) and Kras(T58I) mutations induce distinct RASopathy phenotypes in mice
por: Wong, Jasmine C., et al.
Publicado: (2020)

Inhibition of BET bromodomain-dependent XIAP and FLIP expression sensitizes KRAS-mutated NSCLC to pro-apoptotic agents
por: Klingbeil, Olaf, et al.
Publicado: (2016)

Short report: Performance evaluation of the Idylla™ KRAS and EGFR mutation tests on paraffin-embedded cytological NSCLC samples
por: Offerman, Saskia, et al.
Publicado: (2021)

Computational Analysis of KRAS Mutations: Implications for Different Effects on the KRAS p.G12D and p.G13D Mutations
por: Chen, Chih-Chieh, et al.
Publicado: (2013)

KRAS-mutation incidence and prognostic value are metastatic site-specific in lung adenocarcinoma: poor prognosis in patients with KRAS mutation and bone metastasis
por: Lohinai, Zoltan, et al.
Publicado: (2017)

KRAS mutational analysis for colorectal cancer: Application: Pharmacogenomic
por: Wang, Grace, et al.
Publicado: (2010)

Novel KRAS Gene Mutations in Sporadic Colorectal Cancer
por: Naser, Walid M., et al.
Publicado: (2014)

Apatinib in the treatment of advanced lung adenocarcinoma with KRAS mutation
por: Zeng, Da-xiong, et al.
Publicado: (2017)

Pancreatic cyst fluid harboring a KRAS mutation
por: Al-Turkmani, M. Rabie, et al.
Publicado: (2019)

KRAS mutations in uterine endometrium are associated with gravidity and parity
por: Inoue, Satoshi, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_lfpofk0r6eimfcqm59beis7s11